Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 11-12/2015

01.06.2015 | original article

Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease

verfasst von: MD PhD Ivana Mikolasevic, Lidija Orlic, Luka Zaputovic, Sanjin Racki, Zlatko Cubranic, Kata Anic, Bosiljka Devcic, Davor Stimac

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

In recent years, nonalcoholic fatty liver disease (NAFLD) was recognized as an important factor in chronic kidney disease (CKD) pathogenesis. The concentrations of serum aminotransferases in both chronic dialysis and chronic renal failure (CRF) patients most commonly fall within the lower end of the range of normal values. The aim of the present study was to investigate the usefulness of four liver tests and four biological scores in detection of NAFLD in comparison with transient elastography (TE) findings in different groups of patients.

Methods

The study was cross-sectional analysis collected data from a single tertiary care center. Of 202 patents there were 52 patients with CKD, 50 patients with end-stage renal disease (ESRD) treated with haemodialysis (HD), 50 renal transplant recipients (RTRs) and 50 patients with proven coronary heart disease (CHD). Fifty sex- and age-matched individuals without NAFLD and with normal liver and kidney function tests served as controls. With the help of TE (FibroScan®, Echosense SA, Paris, France), liver stiffness was selected as the parameter to quantify liver fibrosis and Controlled Attenuation Parameter (CAP) was used to detect and quantify liver steatosis.

Results

According to the CAP findings 76.9 %CKD patients, 82 %HD patients, 74 %RTRs and 69.1 % CHD patients had CAP > 238 dB.m−1 and thus by definition NAFLD. We have found that ALT, AST and GGT levels were positively correlated with CAP values while ALT and AST showed positive correlation with liver stiffness acquired with TE only in CHD patients. According to TE findings APRI (AUC 0.796) and FIB-4 (AUC 0.790) scores were correlated with the presence of fibrosis, while HIS score was correlated with the presence of steatosis (AUC 0.867) only in CHD patients.

Conclusion

Liver tests and biological scores are not useful for NAFLD detection in CRF patients. TE with CAP provides the opportunity of noninvasive screening for NAFLD as well as liver fibrosis in patients with CRF.
Literatur
1.
Zurück zum Zitat Dowman JK, Tomlinson JW, Newsome N. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525–40. PubMedCentralPubMedCrossRef Dowman JK, Tomlinson JW, Newsome N. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525–40. PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Mikolasevic I, Racki S, Zaputovic l, Lukenda V, Milic S, Orlic L. Nonalcoholic fatty liver disease (NAFLD); a new risk factor for adverse cardiovascular events in dialysis patients. Med Hypotheses. 2014;82:205–8. PubMedCrossRef Mikolasevic I, Racki S, Zaputovic l, Lukenda V, Milic S, Orlic L. Nonalcoholic fatty liver disease (NAFLD); a new risk factor for adverse cardiovascular events in dialysis patients. Med Hypotheses. 2014;82:205–8. PubMedCrossRef
3.
Zurück zum Zitat Mikolasevic I, Racki S, Lukenda V, Pavletic-Persic M, Milic S, Orlic L. Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction. Med Hypotheses. 2014;82:36–9. PubMedCrossRef Mikolasevic I, Racki S, Lukenda V, Pavletic-Persic M, Milic S, Orlic L. Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction. Med Hypotheses. 2014;82:36–9. PubMedCrossRef
4.
Zurück zum Zitat Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–40. PubMedCrossRef Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235–40. PubMedCrossRef
5.
Zurück zum Zitat Farrel GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112. CrossRef Farrel GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112. CrossRef
6.
Zurück zum Zitat Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. PubMedCentralPubMedCrossRef Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166–71. PubMedCentralPubMedCrossRef Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166–71. PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Hamad AA, Khalil AA, Connolly V, Ahmed MH. Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration. Arab J Gastroenterol. 2012;13:161–5. PubMedCrossRef Hamad AA, Khalil AA, Connolly V, Ahmed MH. Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration. Arab J Gastroenterol. 2012;13:161–5. PubMedCrossRef
9.
Zurück zum Zitat Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L. Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography. Kidney Blood Press Res. 2013;37:305–10. PubMedCrossRef Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L. Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography. Kidney Blood Press Res. 2013;37:305–10. PubMedCrossRef
10.
Zurück zum Zitat Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325–35. PubMedCrossRef Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325–35. PubMedCrossRef
11.
Zurück zum Zitat Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–35. PubMedCrossRef Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825–35. PubMedCrossRef
12.
Zurück zum Zitat Wong Lai-Hung G. Update of liver fibrosis and steatosis with transiet elastography (Fibroscan®). Gastroenterol Rep. 2013;1(1):19–26. doi:10.1093/gastro/got007. CrossRef Wong Lai-Hung G. Update of liver fibrosis and steatosis with transiet elastography (Fibroscan®). Gastroenterol Rep. 2013;1(1):19–26. doi:10.1093/gastro/got007. CrossRef
13.
Zurück zum Zitat de Lédinghen V Vergniol J Foucher J Merrouche W le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–8. PubMedCrossRef de Lédinghen V Vergniol J Foucher J Merrouche W le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–8. PubMedCrossRef
14.
Zurück zum Zitat Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014;9:e91987. PubMedCentralPubMedCrossRef Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014;9:e91987. PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Liberato IR, Lopes EP, Cavalcante MA, Pinto TC, Moura IF, Loureiro Júnior L. Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis. Clinics. 2012;67(2)131–4. PubMedCrossRef Liberato IR, Lopes EP, Cavalcante MA, Pinto TC, Moura IF, Loureiro Júnior L. Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis. Clinics. 2012;67(2)131–4. PubMedCrossRef
16.
Zurück zum Zitat Ono K, Ono T, Matsumata T. The pathogenesis of decreased aspartate amino-transferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Clin Nephrol.1995;43:405–8. PubMed Ono K, Ono T, Matsumata T. The pathogenesis of decreased aspartate amino-transferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Clin Nephrol.1995;43:405–8. PubMed
17.
Zurück zum Zitat Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotrasnferase levels. Ann Int Med. 2002;137:1–9. PubMedCrossRef Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotrasnferase levels. Ann Int Med. 2002;137:1–9. PubMedCrossRef
18.
Zurück zum Zitat Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–80. PubMedCrossRef Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–80. PubMedCrossRef
19.
Zurück zum Zitat Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014;37:1729–36. PubMedCrossRef Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014;37:1729–36. PubMedCrossRef
20.
Zurück zum Zitat Locatelli F, Pozzoni P, Tentori F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant. 2003;18(Suppl 7):vii2–9. PubMedCrossRef Locatelli F, Pozzoni P, Tentori F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant. 2003;18(Suppl 7):vii2–9. PubMedCrossRef
21.
Zurück zum Zitat Cuevas X, García F, Martín-Malo A, Fort J, Lladós F, Lozano J, et al. Risk factor associated with cardiovascular morbidity and mortality in Spanish incident hemodialysis patients: two-year results from ANSWER study. Blood Purif. 2012;33:21–9. PubMedCrossRef Cuevas X, García F, Martín-Malo A, Fort J, Lladós F, Lozano J, et al. Risk factor associated with cardiovascular morbidity and mortality in Spanish incident hemodialysis patients: two-year results from ANSWER study. Blood Purif. 2012;33:21–9. PubMedCrossRef
22.
Zurück zum Zitat Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20:1048–56. PubMedCrossRef Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20:1048–56. PubMedCrossRef
23.
Zurück zum Zitat Hricik D. Metabolic syndrome in kidney transplantation: management of risk factors. Clin J Am Soc Nephrol. 2011;6:1781–5. PubMedCrossRef Hricik D. Metabolic syndrome in kidney transplantation: management of risk factors. Clin J Am Soc Nephrol. 2011;6:1781–5. PubMedCrossRef
24.
Zurück zum Zitat Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;378:1419–27. PubMedCrossRef Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;378:1419–27. PubMedCrossRef
25.
Zurück zum Zitat Mikolasevic I, Jelic I, Sladoje-Martinovic B, Orlic L, Zivcic-Cosic S, Vuksanovic-Mikulicic S, et al. Metabolic disorders in renal transplant recipients. Acta Med Croatica. 2012;66:235–41. PubMed Mikolasevic I, Jelic I, Sladoje-Martinovic B, Orlic L, Zivcic-Cosic S, Vuksanovic-Mikulicic S, et al. Metabolic disorders in renal transplant recipients. Acta Med Croatica. 2012;66:235–41. PubMed
26.
Zurück zum Zitat Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118:96–98. PubMedCrossRef Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118:96–98. PubMedCrossRef
27.
Zurück zum Zitat Berziggoti A. Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: Controlled attenuation parameter for steatosis. J Hepatol 2014;60:910–2. CrossRef Berziggoti A. Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: Controlled attenuation parameter for steatosis. J Hepatol 2014;60:910–2. CrossRef
28.
Zurück zum Zitat de Lédinghen V, Vergniol J, Capdepont M, Chermark F, Hiriart JB, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014;60:1026–31. PubMedCrossRef de Lédinghen V, Vergniol J, Capdepont M, Chermark F, Hiriart JB, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014;60:1026–31. PubMedCrossRef
29.
Zurück zum Zitat Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur J Gastroenterol Hepatol. 2013;25:1330–4. PubMedCrossRef Yilmaz Y, Ergelen R, Akin H, Imeryuz N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur J Gastroenterol Hepatol. 2013;25:1330–4. PubMedCrossRef
30.
Zurück zum Zitat Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res. 2013. http://​dx.​doi.​org/​10.​1111/​hepr.​12094 [Epub ahead of print]. Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res. 2013. http://​dx.​doi.​org/​10.​1111/​hepr.​12094 [Epub ahead of print].
31.
Zurück zum Zitat Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 2014;34:102–9. PubMedCrossRef Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 2014;34:102–9. PubMedCrossRef
32.
Zurück zum Zitat Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2014;29:1470–6. PubMedCrossRef Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2014;29:1470–6. PubMedCrossRef
33.
Zurück zum Zitat Mi YQ, Shi QY, Xu L, Shi RF, Liu YG, Li P, Shen F, Lu W, Fan JG. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using fibroscan(®): validation in chronic hepatitis B. Dig Dis Sci. 2015;60:243–51. PubMedCrossRef Mi YQ, Shi QY, Xu L, Shi RF, Liu YG, Li P, Shen F, Lu W, Fan JG. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using fibroscan(®): validation in chronic hepatitis B. Dig Dis Sci. 2015;60:243–51. PubMedCrossRef
34.
Zurück zum Zitat Yilmaz Y, Yesil A, Gerin F, Ergelen R, Akin H, Celikel ÇA, Imeryuz N. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scand J Gastroenterol. 2014;49:611–6. PubMedCrossRef Yilmaz Y, Yesil A, Gerin F, Ergelen R, Akin H, Celikel ÇA, Imeryuz N. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scand J Gastroenterol. 2014;49:611–6. PubMedCrossRef
35.
Zurück zum Zitat Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:503–8. PubMedCrossRef Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:503–8. PubMedCrossRef
36.
Zurück zum Zitat Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013;58:1007–19. PubMedCrossRef Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013;58:1007–19. PubMedCrossRef
Metadaten
Titel
Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease
verfasst von
MD PhD Ivana Mikolasevic
Lidija Orlic
Luka Zaputovic
Sanjin Racki
Zlatko Cubranic
Kata Anic
Bosiljka Devcic
Davor Stimac
Publikationsdatum
01.06.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 11-12/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0757-z